Clinical trial for first-ever treatment of radiation necrosis

Radiotherapy saves countless lives, but in rare cases, it can cause a debilitating, long-term complication when used on the brain. Around three to five percent of patients who receive radiation for brain tumours, or arteriovenous malformations (AVM), develop radiation necrosis, where the brain tissue around the targeted lesion becomes injured and dies. A new trial is the first in the world to intra-arterially deliver a single, small dose of bevacizumab, a cancer drug known by the name of Avastin, directly to the area of the brain affected by radiation necrosis.
Medical Xpress